Department of Intensive Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Queensland University of Technologygrid.1024.7, Brisbane, Queensland, Australia.
Microbiol Spectr. 2022 Jun 29;10(3):e0056922. doi: 10.1128/spectrum.00569-22. Epub 2022 Apr 25.
Although recent reports of extensively antibiotic-resistant strains have highlighted the importance of Morganella morganii as an emerging pathogen, the epidemiology of serious infections due to this organism is not well defined. The objective of this study was to determine the incidence, determinants, and outcomes of Morganella morganii bloodstream infections (BSIs). Retrospective, population-based surveillance for Morganella morganii BSIs was conducted in Queensland, Australia, in 2000 to 2019; 709 cases were identified, for an annual incidence of 9.2 cases per million population. Most cases were of community onset, with 280 (39.5%) community-associated cases and 226 (31.9%) health care-associated cases. Morganella morganii BSIs were rare in children and young adults, and the incidence increased markedly with advancing age. The most common foci of infection were skin and soft tissue (131 cases [18.5%]), genitourinary (97 cases [13.7%]), and intraabdominal (90 cases [12.7%]). Most patients (580 cases [81.8%]) had at least one comorbid medical illness, with diabetes mellitus (250 cases [35.3%]), renal disease (208 cases [29.3%]), and congestive heart failure (167 cases [23.6%]) being most prevalent. Resistance to one or more of quinolones, co-trimoxazole, aminoglycosides, or carbapenems was observed in 67 cases (9.5%), and this did not change significantly over the study. The 30-day all-cause case fatality rate was 21.2%, and increasing age, nonfocal infection, heart failure, dementia, and cancer were independently associated with increased risk of death. Morganella morganii BSIs are increasing in our population, and elderly male subjects and individuals with comorbidities are at highest risk. Although antibiotic resistance is not a major contributor to the current burden in Queensland, ongoing surveillance is warranted. Recent reports of extensively antibiotic-resistant strains have highlighted the importance of Morganella morganii as an emerging pathogen. Despite its present and evolving importance as an agent of human disease, there is a limited body of literature detailing the epidemiology of serious infections due to Morganella morganii. Therefore, the objectives of this study were to examine the incidence and determinants of Morganella morganii BSIs and to examine risk factors for death in a large Australian population in 2000 to 2019.
尽管最近有大量报道称广泛耐药菌株的出现凸显了摩根摩根菌作为一种新兴病原体的重要性,但该病原体引起的严重感染的流行病学情况尚不清楚。本研究的目的是确定摩根摩根菌血流感染(BSI)的发生率、决定因素和结局。2000 年至 2019 年,在澳大利亚昆士兰州进行了摩根摩根菌 BSI 的回顾性、基于人群的监测;共发现 709 例病例,年发病率为每百万人 9.2 例。大多数病例为社区发病,其中社区相关病例 280 例(39.5%),医疗保健相关病例 226 例(31.9%)。儿童和青年中摩根摩根菌 BSI 很少见,发病率随年龄增长显著增加。最常见的感染部位是皮肤和软组织(131 例[18.5%])、泌尿生殖系统(97 例[13.7%])和腹腔内(90 例[12.7%])。大多数患者(580 例[81.8%])至少有一种合并症,其中糖尿病(250 例[35.3%])、肾脏疾病(208 例[29.3%])和充血性心力衰竭(167 例[23.6%])最为常见。67 例(9.5%)对一种或多种喹诺酮类、复方磺胺甲噁唑、氨基糖苷类或碳青霉烯类药物耐药,且在研究期间无显著变化。30 天全因病死率为 21.2%,年龄增长、非局灶性感染、心力衰竭、痴呆和癌症与死亡风险增加独立相关。摩根摩根菌 BSI 在我们的人群中不断增加,老年男性和合并症患者的风险最高。尽管抗生素耐药性不是昆士兰州目前负担的主要原因,但需要持续监测。最近有关广泛耐药菌株的报告强调了摩根摩根菌作为一种新兴病原体的重要性。尽管摩根摩根菌作为人类疾病的病原体目前具有重要意义并在不断发展,但有关摩根摩根菌引起的严重感染的流行病学资料有限。因此,本研究的目的是检查 2000 年至 2019 年期间,在澳大利亚大型人群中摩根摩根菌 BSI 的发生率和决定因素,并检查死亡的危险因素。